27 agosto 2025 – dsm-firmenich successfully sold Pentapharm AG and its Brazilian sister company Pentapharm do Brasil Comércio e Exportação Ltda. to Orlando Capital V. Pentapharm is a leading provider of biological active ingredients for pharmaceutical and diagnostic applications, with unique expertise in the field of hemostasis. In the pharmaceutical sector, the company offers biological APIs for blood coagulation management, which are used particularly in coagulation disorders and surgical applications. The diagnostics portfolio includes a broad range of products for hemostasis diagnostics – including ready-to-use test kits, substrates, inhibitors, biochemical reagents, and enzymes derived from snake venom. In addition, Pentapharm manufactures natural bioactive ingredients for cosmetic applications in the skincare segment.

Walder Wyss advised dsm-firmenich on all Swiss law and tax aspects of this transaction. The team was led by Michelle Bruni (Managing Associate, Corporate/M&A and Tax) and included Alexander Gutmans (Partner, Corporate/M&A) and Simon Olstein (Senior Associate, Corporate/M&A).